新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价△

doi:10.3969/j.issn.1002-3070.2011.01.012

实用肿瘤学杂志 ›› 2011, Vol. 25 ›› Issue (1): 40-45.doi: 10.3969/j.issn.1002-3070.2011.01.012

新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△

印明柱, 娄阁, 陈秀玮, 顾泰华

哈尔滨医科大学附属第三医院(哈尔滨 150081)

收稿日期:2010-10-19 出版日期:2011-01-25 发布日期:2012-02-21
通讯作者: 娄阁,E-mail:Louge@ems.hrbmu.edu.cn
作者简介:印明柱,男,研究生,从事妇科肿瘤临床及基础研究
基金资助:
中华医学会资助课题(CAMB022010)

The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer

YIN Mingzhu,LOU Ge,CHEN Xiuwei,GU Taihua

Department of Gynecology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081

Received:2010-10-19 Online:2011-01-25 Published:2012-02-21

摘要/Abstract

摘要：

目的本研究的目的是比较ⅠB2~ⅡB期局部晚期宫颈癌新辅助化疗后根治性手术与同步放化疗的远期生存情况。方法回顾性分析从2000年1月—2004年12月间ⅠB2~ⅡB期局部晚期宫颈癌共222例,将其分为二组:新辅助化疗+根治性全子宫切除术+盆腔淋巴结切除术共155例;同步放化疗组67例。所有患者最长随访时间为114个月,最短随访时间为54个月,中位随访时间为72.6个月。且对所有可能影响无瘤生存时间和总生存时间的高危因素进行评估。结果本研究中位随访时间为72.6个月,新辅助化疗后根治性手术组和同步放化疗组5年无瘤生存率分别是88.39%和70.94%,两组比较有统计学意义(P=0.006);而5年总生存率分别为88.52%和72.91%,两组比较有统计学意义(P=0.0004)。在Cox风险回归模型中,调整宫颈癌患者的年龄、病理分型后,结果显示:接受新辅助化疗后根治性手术组和同步放化疗组治疗的宫颈癌患者5年无瘤生存时间有明显差异(HR=2.765,95%CI:1.446~5.288,P=0.0021);在5年总生存时间上也有显著性差异(HR=3.516,95%CI:1.822~6.784,P=0.0002)。结论本研究ⅠB2~ⅡB期局部晚期宫颈癌新辅助化疗后根治性手术组在无瘤生存时间和总生存时间方面显著优于同步放化疗组。

关键词: 宫颈癌, 新辅助化疗, 根治性手术, 同步放化疗

Abstract:

Objective The purpose of this study is to compare long-term survival of neoadjuvant chemotherapy followed by radical hysterectomy with concurrent chemoradiotherapy in locally advanced cervical cancer.Methods A total of 222 stageⅠB2-ⅡB locally advanced cervical cancer cases from January 2000 to December 2004 were analyzed retrospectivly.All the cases were divided into two groups:155 cases of neoadjuvant chemotherapy followed by radical hysterectomy with pelvic lymph node dissection(NACT + RS group);67 cases of concurrent chemoradiotherapy group(CCRT group).Patients were followed up from 54 to 114 months,NACT group patients were followed up for more than 72.6 months,all risk factors that may affect the disease-free survival(DFS)and overall survival(OS)were assessed.The NACT+RS group had significantly higher survival rates than both the CCRT(DFS:hazard ratio=2.765,P=0.0021;OS:hazard ratio=3.516,P=0.0002)groups.Results In this study,median follow-up time was 72.6 months,the five-year DFS rates of the NACT+RS and CCRT groups were 88.39% and 70.94%,respectively(P=0.006),while the five-year OS rates were 88.52% and 72.91%,respectively(P=0.0004).Conclusion There was no significant difference in both the short-term effect and complete remission rate between NACT + RS group and CCRT group on stage ⅠB2-ⅡB locally advanced cervical cancer patients;it was significantly better on DFS and OS of NACT + RS group than that of CCRT group.

Key words: Cervical carcinoma, Neoadjuvant chemotherapy, Radical hysterectomy, Concurrent chemoradiotherapy

中图分类号:

R737.33

印明柱, 娄阁, 陈秀玮, 顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△[J]. 实用肿瘤学杂志, 2011, 25(1): 40-45.

YIN Mingzhu,LOU Ge,CHEN Xiuwei,GU Taihua. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(1): 40-45.

[1]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[2]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.
[3]	成海燕, 马晶, 冯紫微, 黄可金, 王玉霞, 张云艳. 抑癌基因PRDM5在HPV16病毒致宫颈鳞癌发生过程中的作用研究[J]. 实用肿瘤学杂志, 2018, 32(6): 483-487.
[4]	付艳丽, 余杨, 卫玮, 邹晶晶, 孙翔. 高危型人乳头状瘤病毒载量和Th1/Th2不均衡表达预测宫颈癌变进程的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 533-537.
[5]	秦文艳综述, 卢艳审校. 宫颈癌前哨淋巴结微转移的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 571-574.
[6]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[7]	孟志英, 于松涛, 张晶晶, 金惠敏. 宫颈癌下颌骨转移1例报告并文献复习[J]. 实用肿瘤学杂志, 2018, 32(2): 122-124.
[8]	毕琦玲, 周立红, 韩毅敏. HOX基因与妇科肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 140-143.
[9]	王庆辉, 孙悦, 姜万维. 探讨氟比洛芬酯应用于宫颈癌手术术后镇痛的临床效果[J]. 实用肿瘤学杂志, 2018, 32(1): 33-37.
[10]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[11]	雷蕾, 叶庆华, 王国增, 黄贤莉, 吴乾渝. Aurora-A在宫颈癌及癌前病变中的表达以及与HPV感染的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(6): 494-499.
[12]	于德洋, 杨姗姗, 云惟康, 冯丽娜, 白彦灵. 宫颈癌术后容积弧形调强与固定野动态调强放疗技术的剂量学比较[J]. 实用肿瘤学杂志, 2017, 31(2): 152-155.
[13]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[14]	曲亚兰, 谢宝芳, 李丹阳. 流式细胞术联合阴道镜活检在宫颈癌和癌前病变筛查中的意义[J]. 实用肿瘤学杂志, 2017, 31(1): 31-34.
[15]	杨毅，丁妍，于爱清，严世荣. 自噬对宫颈癌细胞增殖和迁移能力的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 481-486.

新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△

The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价